Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDI01 Suspension in Idiopathic Pulmonary Fibrosis (Adaptive Phase III, Stage 1)
CTR20254871Phase 3Active
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TDI01 in idiopathic pulmonary fibrosis (IPF), sponsored by Beijing Tide Pharmaceutical Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
TDI01
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20254871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254871.